1. Background {#sec1}
=============

The cerebrospinal fluid (CSF) concentrations of the 42 amino acid form of amyloid β (Aβ~42~), total tau protein (T-tau), and phosphorylated tau (P-tau) are core biomarkers of Alzheimer\'s disease (AD) [@bib1] and are incorporated in the clinical diagnostic process [@bib2]. Largely constituting the neuropathological hallmarks of AD [@bib3], these proteins are also integral to the validation and study of AD models in a research context.

While tau is soluble and concentrations remain relatively stable over a range of conditions [@bib4], [@bib5], [@bib6], Aβ~42~ is well known to be highly labile and prone to aggregate, a property that underpins a range of dynamic structures and their contribution to the disease process [@bib7]. These properties make Aβ~42~ concentrations susceptible to variation in the preanalytical process. Factors potentially include CSF collection technique [@bib8], diurnal collection time [@bib9], interval between collection and freezing [@bib10], [@bib11], temperature [@bib12], pH [@bib13], sample matrix composition [@bib14], [@bib15], sample exposure to storage surfaces [@bib6], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], and assay measurement variation [@bib23], [@bib24], [@bib25], [@bib26], [@bib27]. Several articles have presented studies providing data from assessments of multiple factors [@bib5], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32].

Further to preanalytical factors, concentrations of CSF Aβ also vary between individuals [@bib33]; thus, individuals with constitutively high or low quantities of Aβ~42~ relative to chosen diagnostic "cut points" may be vulnerable to misinterpretation of test results. Recent meta-analysis shows that when comparing AD versus nondemented controls and non-AD dementias, CSF Aβ~42~ has a pooled sensitivity of 0.80 (95% confidence interval = 0.78--0.82) and a pooled specificity of 0.76 (95% confidence interval = 0.74--0.78) [@bib34]. Increasingly, reports suggest improved diagnostic and mild cognitive impairment--AD conversion predictive power when Aβ~42~ is considered in ratio to Aβ~40~ [@bib1], [@bib15], [@bib16], [@bib31], [@bib35], [@bib36]. Aβ~40~ has been shown to be the most abundant Aβ peptide in the adult human brain [@bib37] and does not generally have strong aggregative tendencies under physiological conditions or in vitro. Owing to this, CSF Aβ~40~ has been proposed as a proxy for total Aβ production [@bib33], [@bib38]. Another relatively abundant peptide, Aβ~38~, has also demonstrated utility in ratio with Aβ~42~ [@bib35]. This is welcome news as, although biomarkers have facilitated earlier and more accurate diagnosis, improved patient group enrichment in current clinical trial design (i.e. more accurate, earlier disease phase biomarkers) is urgently required [@bib39].

The aim of the present study was to extend previous work on the effect of surface exposure on Aβ peptide concentration by assessing the impact on ratios of Aβ~42~:Aβ~40~, Aβ~42~:Aβ~38~, and Aβ~40~:Aβ~38~. Aβ~40~:Aβ~38~ is not immediately relevant to the clinic, but better understanding of the relationship between production and interaction of different Aβ fragments may prove useful to future understanding of AD pathobiology. In addition to CSF, we also examined cell culture media (CM) from human glutamatergic cortical neurons derived from induced pluripotent stem cells (iPSCs). Neurons differentiated from the iPSCs of AD and non-AD donors can act as disease-relevant models with a fully human genetic background. Aβ secreted from these cells into the CM represents a key biomarker for AD-relevant neurobiology. In this context, ratios of Aβ are increasingly used to understand nuances of amyloidogenic pathways [@bib40], and it is important to expand knowledge of preanalytical factors affecting Aβ measurement in this medium.

2. Methods {#sec2}
==========

2.1. Preparation of CSF {#sec2.1}
-----------------------

This study used de-identified CSF from patients of unknown disease status. Ethical approval was received from the regional ethics board at the University of Gothenburg for the CSF pools used in this study. Samples were collected by lumbar puncture. All lumbar punctures were conducted before 13:00, between L3/L4 and L4/L5 in a sitting or side-laying position. Ten milliliters of CSF was collected at ambient room temperature into a 10-mL PP tube (Sarstedt, Nümbrecht, Germany; cat. 62.9924.284). In the case of visible blood contamination, the CSF was discarded and tap continued in a new tube once bleeding had stopped. Samples selected for inclusion had no erythrocyte contamination visible to the eye. Samples were centrifuged at 2200 relative centrifugal force for 10 minutes at 20°C, transferred to another 10-mL tube (Sarstedt; cat. 62.9924.284), and stored at −80°C. CSF samples were then thawed at 21°C for 1 hour to pool CSF to sufficient volume for experiment in Sarstedt 2-mL PP tubes (cat. 72.694.406), refrozen at −80°C, and thawed (21°C for 1 hour) for assay. CSF was transported on dry ice by international courier and received, frozen, within 24 hours of sending, and immediately stored at −80°C on reception.

2.2. Preparation of cell CM {#sec2.2}
---------------------------

The N2B27 cell CM used in this study was composed of a 1:1 solution of DMEM/F12 + GlutaMax-l (1×) (Life Technologies; cat. 10565018) and Neurobasal Medium (1×) (Life Technologies; cat. 12348017) with the following supplements: 1× N2 supplement (Life Technologies; cat. 17502-048), 1× B27 supplement (Life Technologies; cat. 17504-044), 100-μM MEM nonessential amino acids (Life Technologies; cat. 11140-050), 100-μM 2-mercaptoethanol (Life Technologies; cat. 31350-010), 50-U/mL penicillin and 50-μg/mL streptomycin (Life Technologies; cat. 15070063), 5-μg/mL insulin (Sigma-Aldrich; cat. I9278), and 1-mM glutamine (Life Technologies; cat. no. 25030-024). Fresh N2B27 was made every 7 days and stored at 4°C.

2.3. Neuronal culture {#sec2.3}
---------------------

Glutamatergic cortical neurons were generated from human iPSCs following a protocol previously described [@bib41], [@bib42], [@bib43]. Briefly, iPSCs (cultured on Geltrex and fed with Essential 8) were induced toward a neuronal fate by treatment with N2B27 media supplemented with SMAD (a family of human protein homologues of the drosophila 'mothers against decapentaplegic' \[Mad\] and the proteins encoded by the *C. elegens* gene 'small body size' \[Sma\]) inhibitors, SB431542 (10 μM) and Dorsomorphin (1 μM), for 12 days. Neuronal precursor colonies were expanded on laminin-coated plates and maintained in N2B27 media until cultures of mature cortical neurons were generated, at least 80 days after induction. Five different cell lines were used in this study: CTRL and ND were fibroblast-derived iPSC lines from nondegenerative controls, generated using retroviral transduction (obtained from the laboratory of Dr Tilo Kunath). SHEF6 was a human embryonic stem cell line obtained from the UK Stem Cell Bank. APP (derived from an amyloid precursor protein V717I mutation patient) and PSEN (derived from a presenilin-1 T113-114ins intron 4 deletion mutation patient) were fibroblast-derived iPSC lines generated using retroviral transduction, obtained from StemBANCC. Cell CM were collected after 4-day incubation in VWR 15-mL PP tubes (cat: 21008-216), pooled and centrifuged at 2000 relative centrifugal force for 5 minutes at 21°C. Supernatant was aliquoted in Sarstedt 2-mL PP tubes (cat. 72.694.406), stored at −80°C, and thawed at 21°C immediately before assay.

2.4. Volume experiments {#sec2.4}
-----------------------

To investigate the effect of storage volume on the ratios of Aβ peptides, each CSF (n = 8) and CM (n = 6) sample was thawed and aliquoted into Sarstedt 2-mL PP tubes (cat. 72.694.406) in a volume series: 1000, 500, 250, 125, and 100 μL. Aliquots were refrozen at −80°C and later thawed at 21°C for 1 hour and assayed for Aβx-38/x-40/x-42 using a Meso Scale Discovery V-PLEX Aβ peptide kit (6E10). Assays were performed on a Meso Scale Discovery SECTOR 6000, according to manufacturer protocol, which is freely available.

To examine the contribution of the pipette to any effect, a separate group of samples (CSF n = 2 and CM n = 2) were aliquoted into four different volumes (100, 250, 500, and 1000 μL) and, immediately before sample dilution during assay, each volume for each sample was mixed with a varying number of pumps (0, 5, 10, and 20) with a pipette tip (TipOne; Starlab, Milton Keynes; cat. S1113-1700). Tips used for samples given the 0 pump treatment were therefore not prewetted.

All samples were added to the assay plate in duplicate by multichannel in randomized, double-blind order. All samples and reagents of volume \<5 mL were mixed by vortex (Vortex-Genie 2; Scientific Industries) at speed setting 10 for 5 seconds, and all samples and reagents of volume \>5 mL were mixed on a roller for 5 minutes. Pipette tips (TipOne; Starlab, Milton Keynes; cat. S1112-1720, cat. S1113-1700, and cat. S1110-3700) were prewetted with three pumps when aspirating all solutions unless otherwise stated. The same pipette tip was used to create the volume series of each sample.

2.5. Serial transfer experiments {#sec2.5}
--------------------------------

Each CSF (n = 9) and CM (n = 5) sample was thawed, aliquoted into Sarstedt 2-mL PP tubes at a volume of 1000 μL, refrozen at −80°C, and later thawed for assay. The sample was mixed by vortex and transferred from the storage aliquot (tube 0) to seven consecutive Sarstedt 2-mL PP tubes (tubes 1--7), leaving 100 μL of sample in each tube. This process took approximately 10 minutes to complete. Samples were then assayed immediately for Aβx-38/x-40/x-42 as described for the volume experiment. All samples were added to the assay plate in duplicate by multichannel in randomized, double-blind order. Mixing practice and pipette tips used were as described in section [2.4](#sec2.4){ref-type="sec"}. The same pipette tip was used to create the transfer series of each sample. Data from two CSF samples previously reported (S12 and S13 in this study, previously AD and CT [@bib36]) were included in the analyzed data set. These samples were prepared according to the same protocol just described and were included to bolster the power of the data set.

2.6. Statistical analysis {#sec2.6}
-------------------------

The relationship between analyte measurement and sample treatment (volume or transfer step) was assessed by mixed model analysis. Data normality was assessed by histogram, qq-plot, and Shapiro-Wilk test, and linearity was assessed by a scatterplot of the residual variance. All analyses set α at 0.05 and confidence intervals at 95%. The formula used for the mixed model was lme(sample concentration ∼ treatment + X, random = ∼1\|sample) + ε, where the dependent variable is "sample concentration"---the average of duplicate concentration (or ratio) values of a given Aβ peptide in pg/mL (numeric data), the fixed effect variable is "treatment"---the volume or transfer series as relevant (numeric data), X represents other fixed effects (such as disease status, cell type, assay plate, and sample pooling status) where these variables were relevant, and the random effect variable is "sample"---variation unaccounted for differences samples (factor data). "∼1\|" specifies an independent intercept for each sample. ε represents residual variation not accounted for by the stated parameters of the model.

While data from the volume study met the mixed model\'s assumption of linearity, the data from the transfer study did not. To meet this requirement, a separate analysis was conducted wherein average concentration was transformed by the natural logarithm (ln) and used as the dependent variable. To calculate the proportional change per treatment unit, "e" was exponentiated to the power of the model\'s output coefficient. Graphs were composed using the ggplot2 package in R. Intra- and inter-assay percentage coefficients of variance were calculated according to ISO 5725-2 standards [@bib44].

3. Results {#sec3}
==========

3.1. Assay variation {#sec3.1}
--------------------

Intra- and inter-assay variations were calculated from the concentrations of an internal control CSF sample included in assay plates in both volume and transfer studies. Levels of variation (intra- and inter-assay percentage coefficients of variance, respectively) for Aβ~42~ (4.3% and 9.9%), Aβ~40~ (4.5% and 9.5%), and Aβ~38~ (1.6% and 5.3%) were within what is generally considered acceptable range for research assays (\<20%).

3.2. Effect of storage volume on Aβ peptide ratio {#sec3.2}
-------------------------------------------------

Detectable Aβ~42~/Aβ~40~/Aβ~38~ concentration was observed to be significantly lower (all *P* \< .001) in samples of smaller storage volumes in both CSF and CM ([Figs. 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Results from these data predict a concentration change of Aβ~42~: 1.1 pg/mL (0.6%), Aβ~40~: 9.2 pg/mL (0.3%), and Aβ~38~: 3.1 pg/mL (0.2%), for every 10-μL change in CSF storage volume, and a concentration change of Aβ~42~: 0.5 pg/mL (0.3%), Aβ~40~: 2.5 pg/mL (0.2%), and Aβ~38~: 0.4 pg/mL (0.1%), for every 10 μL change in CM storage volume ([Table 1](#tbl1){ref-type="table"}). Results for CSF Aβ~42~ are highly consistent with those previously reported for control CSF (a change of 0.95 pg/mL per 10 μL) [@bib6].Fig. 1Effect of storage volume on CSF Aβ. Results in CSF show the concentration of Aβ~42~, Aβ~40~, and Aβ~38~ decreased with decreased storage volume (A, C, E). Concentration of Aβ~42~ decreased proportionally more than Aβ~40~ (B) and Aβ~38~ (D) with lower storage volume, resulting in a decrease in the Aβ~42~:Aβ~40~ and Aβ~42~:Aβ~38~ ratios. (F) Aβ~40~ showed a nonsignificant tendency to decrease more than Aβ~38~, (*P* = .05). Data for sample S8 at 125 μL were excluded due to insufficient volume in the assay well; the line interpolates through this point. Error bars represent standard error of the mean. Abbreviations: CSF, cerebrospinal fluid; Aβ, amyloid β.Fig. 2Effect of storage volume on cell media Aβ. Results in CM show the concentration of Aβ~42~, Aβ~40~, and Aβ~38~ decreased with decreased storage volume (A, C, E). Concentration of Aβ~42~ decreased proportionally more than Aβ~40~ (B) and Aβ~38~ (D) with lower storage volume, resulting in a decrease in the Aβ~42~:Aβ~40~ and Aβ~42~:Aβ~38~ ratios. (F) Aβ~40~ showed a tendency to decrease more than Aβ~38~, although this was only weakly significant (*P* = .03). Abbreviations: CM, culture media; Aβ, amyloid β.Table 1Summary of resultsTypePeptideStudy% Change per unit*P* (α = 0.05)95% confidence intervalCSFAβ~38~Vol0.245\<.0010.1680.322CSFAβ~40~Vol0.318\<.0010.2020.435CSFAβ~42~Vol0.555\<.0010.4030.707CSFAβ~42~:Aβ~40~Vol0.237\<.0010.1600.313CSFAβ~42~:Aβ~38~Vol0.310\<.0010.2050.415CSFAβ~40~:Aβ~38~Vol0.073.054−0.0010.148CSFAβ~38~Tra15.756\<.00114.81816.695CSFAβ~40~Tra17.497\<.00116.73418.260CSFAβ~42~Tra22.359\<.00121.17723.541CSFAβ~42~:Aβ~40~Tra4.862\<.0013.9905.734CSFAβ~42~:Aβ~38~Tra6.603\<.0015.4097.796CSFAβ~40~:Aβ~38~Tra1.741\<.0011.1112.372CMAβ~38~Vol0.105\<.0010.0530.156CMAβ~40~Vol0.162\<.0010.1060.217CMAβ~42~Vol0.331\<.0010.2350.427CMAβ~42~:Aβ~40~Vol0.169\<.0010.1040.234CMAβ~42~:Aβ~38~Vol0.226\<.0010.1600.293CMAβ~40~:Aβ~38~Vol0.057.0280.0070.108CMAβ~38~Tra2.411\<.0011.6763.205CMAβ~40~Tra4.789\<.0014.1035.711CMAβ~42~Tra7.786\<.0016.9939.219CMAβ~42~:Aβ~40~Tra3.148\<.0012.3154.082CMAβ~42~:Aβ~38~Tra5.508\<.0014.5326.799CMAβ~40~:Aβ~38~Tra2.436\<.0011.5993.334[^1][^2]

Concordantly, ratios of Aβ~42~:Aβ~40~ and Aβ~42~:Aβ~38~ changed significantly with storage volume. In CSF Aβ~42~:Aβ~40~, change was 0.2% of an initial ratio value per 10 μL (*P* \< .001), and in CSF Aβ~42~:Aβ~38~, change was 0.3% per 10 μL (*P* \< .001) ([Table 1](#tbl1){ref-type="table"}). In CM, change in the Aβ~42~:Aβ~40~ and Aβ~42~:Aβ~38~ ratios were 0.1% and 0.2% of the ratio per 10 μL (*P* \< .001), respectively ([Table 1](#tbl1){ref-type="table"}). The magnitude of change per unit volume was reduced in both CSF and CM ratios versus Aβ~42~ alone. The ratio of Aβ~40~:Aβ~38~ showed a trend toward decreased Aβ~40~, which bordered on significance in CSF (*P* = .054) and CM (*P* = .028) ([Table 1](#tbl1){ref-type="table"}).

3.3. Effect of serial tube transfer on Aβ peptide ratio {#sec3.3}
-------------------------------------------------------

Detectable Aβ~42~/Aβ~40~/Aβ~38~ concentration was observed to decrease significantly (all *P* \< .001) over the transfer series in both CSF and CM ([Figs. 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). Results from untransformed CSF data were highly consistent with observations made of control CSF in a previous study [@bib16]. However, these data violated the model\'s assumption of linearity. Concentration loss in CSF between transfer 0 and transfer 1 was particularly pronounced for Aβ~42~, an effect not observed in CM. The mean difference in Aβ~42~ between transfer 0 and transfer 1 was 95.8 pg/mL (paired, two-tailed t-test *P* \< .001), whereas the mean difference between transfer 1 and the final concentration at transfer 7 was 149.7 pg/mL (paired, two-tailed t-test *P* \< .001). This highlights that, in CSF, the first transfer accounted for 39% of the total Aβ~42~ lost (as compared to Aβ~38~ = 8.8% and Aβ~40~ = 24.1%). The decrease in all Aβ peptides remained significant between transfers 1 and 7 after transfer 0 was removed. This effect was not observed in CM samples.Fig. 3Effect of serial tube transfer on CSF Aβ. Results in CSF show the concentration of Aβ~42~, Aβ~40~, and Aβ~38~ decreased with consecutive transfer of sample to new storage tubes (A, C, E). Concentration of Aβ~42~ decreased proportionally more than Aβ~40~ (B) and Aβ~38~ (D) with each transfer, resulting in a decrease in the Aβ~42~:Aβ~40~ and Aβ~42~:Aβ~38~ ratios. (F) In turn, the rate of Aβ~40~ decrease with each transfer was greater than Aβ~38~. Error bars represent standard error of the mean. Abbreviations: Aβ, amyloid β; CSF, cerebrospinal fluid.Fig. 4Effect of serial tube transfer on cell media Aβ. Results in CM show the concentration of Aβ~42~, Aβ~40~, and Aβ~38~ decreased with consecutive transfer of sample to new storage tubes (A, C, E). Concentration of Aβ~42~ decreased proportionally more than Aβ~40~ (B) and Aβ~38~ (D) with each transfer, resulting in a decrease in the Aβ~42~:Aβ~40~ and Aβ~42~:Aβ~38~ ratios. (F) In turn, the rate of Aβ~40~ decrease with each transfer was greater than Aβ~38~. Abbreviations: CM, culture media; Aβ, amyloid β.

To test whether exaggerated Aβ~42~ loss at first transfer may have been due to adsorption to the pipette tip, we conducted a pilot experiment to measure Aβ~42~ peptide concentration change in response to a varying number of aspirations using the same tip. The number of fluid pumps had no effect on Aβ~42~ peptide concentration in either CSF or CM, indeed paired, two-tailed t-test showed no significant difference between 0 pumps and 5 pumps, although it was observed that measurement variability was greater in the 0 pump group ([Fig. 5](#fig5){ref-type="fig"}). The initial exaggerated decrease in Aβ~42~ cannot therefore be attributed to adsorption to the pipette tip.Fig. 5CSF (SX and SY) and CM (CTRL and ND) Aβ~42~: Effect of mixing by pipette across different storage volumes. Results show the concentration of Aβ~42~ were not significantly affected by different levels of exposure to the pipette tip over a series of different volumes in either CSF or CM. Greater variability between measurements was observed in CSF measurements than those of CM. Error bars represent standard error of the mean. Abbreviations: CM, culture media; Aβ, amyloid β; CSF, cerebrospinal fluid.

To account for nonlinearity, data were transformed by ln and reanalyzed. After ln transformation, Aβ~42~ decrease over serial tube transfers remained exaggerated in relation to Aβ~40~ and Aβ~38~ in both CSF and CM ([Table 1](#tbl1){ref-type="table"}). In CSF, the Aβ~42~:Aβ~40~ ratio decreased by 4.9% per transfer, and the Aβ~42~:Aβ~38~ decreased by 6.6% per transfer ([Table 1](#tbl1){ref-type="table"}). In CM, these were 3.1% and 5.5%, respectively. The decrease per transfer of Aβ~40~:Aβ~38~ was 1.7% in CSF and 2.4% in CM; in both fluids, the decrease of Aβ~40~ relative to Aβ~38~ was significant (*P* \< .001).

4. Discussion {#sec4}
=============

In this study, we explored the effect of storage volume and serial between-tube transfer on the concentration of Aβ~42~/Aβ~40~/Aβ~38~ in human CSF and the CM of human cortical neurons derived from iPSCs. We report a novel finding: First, Aβ peptides are differentially affected by changes in sample surface exposure and raise the implication that subpopulations of Aβ peptide structures may be differentially vulnerable to surface exposure. Second, we show that ratios are less sensitive to surface exposure than peptides considered alone, although the effect is still significant.

4.1. Aβ peptides are differentially vulnerable to surface exposure {#sec4.1}
------------------------------------------------------------------

CSF and CM Aβ~42~/Aβ~40~/Aβ~38~ concentrations decreased as a result of two different PP surface exposure treatments (storage volume and serial tube transfer), closely replicating observations we previously reported in CSF [@bib6], [@bib16]. Results are consistent with irreversible peptide adsorption to the tube surface, although the experiments did not test for this mechanism directly. Importantly, this decrease did not occur at the same rate for each peptide. Ratios of Aβ~42~:Aβ~40~ and Aβ~42~:Aβ~38~ demonstrated that decrease in Aβ~42~ concentration per treatment unit was consistently greater than that observed in Aβ~40~ and Aβ~38~, in both CSF and CM. In addition, Aβ~40~:Aβ~38~ ratios indicated that Aβ~40~ may demonstrate a tendency toward greater concentration loss per treatment than Aβ~38~.

To our knowledge experiments such as these have not previously been published on CM. However, a body of work has been growing on the impact of preanalytical surface adsorption in CSF. Vanderstichele et al. [@bib32] observed significant decreases in Aβ~1--42~ (−13.6%), Aβ~1--40~ (−15.5%), and Aβ~1--38~ (−10.6%) between CSF stored at 1500 μL (Sarstedt; cat. 72.706) and 500 μL (Sarstedt; cat. 72.730.006) in PP tubes, but not in Eppendorf LoBind tubes. They found that the Aβ~42~:Aβ~40~ ratio was not significantly altered by the difference in volume, whereas Aβ~42~:Aβ~38~ was altered by 3.4%. This is in contrast to our model that predicts larger, significant, changes in Aβ~42~:Aβ~40~ (23.7%) and Aβ~42~:Aβ~38~ (30.9%). It is worth noting that the volume effect is closely related to tube dimension [@bib6], [@bib21], and our results represent the difference between 1000 and 100 μL rather than 1500 and 500 μL, which have different relative surface area exposure to the conical portion of the tube. In addition, the tubes used by Vanderstichele et al. for each volume were not the same, and neither matched the tube we tested (Sarstedt; cat. 72.694.007), which may reduce the direct comparability of results. With regard to the preanalytical effects of tube transfer, the observations between this group and our own align more closely. Vanderstichele et al. [@bib32] observed significantly lower concentrations of Aβ~42~ (11.0%), Aβ~40~ (7.3%), and Aβ~38~ (2.7%) in CSF collected into PP tubes. In addition, they report a concentration decrease of Aβ~42~ (42.5%), Aβ~40~ (27.8%), and Aβ~38~ (16.7%) after one transfer between PP tubes (Sarstedt; cat 62.554.502 and either 72.706 or 72.730.006). In comparison, at the first transfer, our results showed a similar decrease of Aβ~42~ (39.0%) and Aβ~40~ (24.1%), but smaller decrease of Aβ~38~ (8.8%).

Willemse et al. [@bib21] reported a 5% decrease (up to 10% in small volume samples) in Aβ~42~ and Aβ~40~ per transfer over four transfers between tubes and that Aβ~42~:Aβ~40~ therefore remained constant over transfer treatment. An effect size of 5%--10% is at odds with the Aβ~42~ (22.3%) and Aβ~40~ (17.5%) decrease per transfer that we observed over equivalent transfers. The tubes used by Willemse et al. (Sarstedt; cat. 72.694.007) are identical to the tubes we studied (Sarstedt; cat. 72.694.406), except that cat. 72.694.406 is certified DNA and RNase free. It is not clear why our data should be divergent, other factors are seemingly involved, and a degree of interlaboratory variation should be taken into consideration until these factors are identified.

Repeated aspirations and ejections from the same tip did not significantly alter Aβ concentration in either CSF or CM. Indeed even when the tip was not prewetted, no effect was seen, contrary to what others have described [@bib21]. Therefore, this cannot account for the initial exaggerated decrease we observed at the first transfer step. Given this, we hypothesize the existence of a subpopulation of Aβ~42~ that is more readily adsorbed to PP and rapidly depleted from solution. This interpretation would fit the work of Vanderstichele et al. [@bib32], but not Willemse et al. [@bib21]. A similar, adsorption-attributed, initial effect on fluorescein-labeled bovine serum albumin (BSA), also found in the B27 fraction of the CM used in our study, has been reported [@bib45]. It is possible that competition for surface binding sites by this and other proteins of the CM matrix might explain why the first transfer step effect was not observed in these samples, although we did not examine fluid protein content as a variable.

Although still not well understood, Aβ monomers, oligomers, and fibrils adopt a range of conformations in solution, and indeed current models highlight the importance of C-terminal sequence for multimeric stability and predict the presence of a laterally exposed hydrophobic "patch" unique to certain Aβ~42~ fibrils [@bib46], [@bib47]. These properties may contribute to differences observed in Aβ~42~ versus Aβ~40~ nucleation rate constants [@bib48], [@bib49] and the range of adsorption dynamics at different polymer surfaces [@bib50], [@bib51]. Our results, which are preliminary, highlight the risk that potentially disease-relevant peptide subpopulations may be differentially vulnerable to loss during preanalytical processes.

4.2. Aβ ratios are less vulnerable to preanalytical surface exposure {#sec4.2}
--------------------------------------------------------------------

Despite disparities in the size of transfer and volume effects between studies on PP tubes, our data and those of others [@bib21], [@bib32] converge on the reduction of preanalytical surface exposure effect when a ratio of Aβ peptides is used. For Aβ~42~:Aβ~40~, the disparity between initial and treatment subsequent result was reduced by approximately 50% (volume) and 75% (transfer) as compared to Aβ~42~ alone ([Table 1](#tbl1){ref-type="table"}). It is difficult to give a hard estimate for the amount of concentration loss necessary to mislead interpretation of the ratio, and this will depend on how close the individual peptide values are to a chosen diagnostic threshold. However, it is reasonable to expect reduction in the range, or "gray zone", of diagnostic uncertainty if preanalytically derived "noise" can be mitigated. This is also relevant to cell models in AD research, where Aβ measurement variability within and between cell lines presents a hindrance to experiment repeatability, which use of ratios may help reduce.

4.3. Limitations {#sec4.3}
----------------

This study was limited by the relatively low number of independent samples used.

4.4. Summary {#sec4.4}
------------

Loss of Aβ~42~ following differential exposure to polypropylene surfaces was significantly greater than Aβ~40~ and Aβ~38~ in both human CSF and neuronal cell CM. In addition, there was a tendency toward a pattern of greater loss of Aβ~40~ relative to Aβ~38~. Despite differences between peptides, Aβ ratios were less strongly affected by storage volume and tube transfer treatments than peptides considered individually. We conclude that the Aβ~42~:Aβ~40~ and Aβ~42~:Aβ~38~ ratios may predispose toward a risk of a false-negative diagnostic result for AD if samples are not treated in a standardized manner, though risk of misinterpretation may be less attendant than to Aβ~42~ alone. Reporting Aβ ratios in concert with individual peptides may reduce misinterpretation of Aβ assay results.Research in Context1.Systematic review: Amyloid β 42 (Aβ~42~):Aβ~40~ ratio has attracted interest as a biomarker for Alzheimer\'s disease (AD) with a number of recent clinical studies demonstrating high sensitivity and specificity. Work on identifying preanalytical factors relevant to the ratio is ongoing. The authors have comprehensively cited this literature.2.Interpretation: Our findings add to growing evidence supporting Aβ~42~:Aβ~40~ and Aβ~42~:Aβ~38~ ratios as reliable biomarkers for AD and expand the experimental perspective beyond cerebrospinal fluid (CSF) to cell media. Significantly we highlight that longer peptides adsorb to polypropylene surfaces, in a context relevant to clinical diagnostics, to a greater extent than shorter peptides.3.Future directions: The manuscript forms a platform for further characterization of peptide-surface interaction for a wider range of Aβ fragments, which may have disease relevance or biomarker utility, and also for identification of factors affecting Aβ measurement from *in vitro* model fluids.
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[^1]: Abbreviations: CM, culture media; Aβ, amyloid β; CSF, cerebrospinal fluid.

[^2]: NOTE. Volume unit is 10 μL, and transfer is 1 transfer. The table is divided into data generated for CSF and CM for storage volume (Vol) and serial transfer (Tra) treatments, respectively. Data are given for Aβ~42~, Aβ~40~, Aβ~38~, and the ratio of these peptides transformed by natural logarithm (ln). Values given in "% Change per unit" are exponentiated coefficients of the mixed model as percent of Aβ concentration (pg/mL) or ratio change per unit of treatment. For the volume treatment, the unit of change is 1 μL, that is, the amount of Aβ lost per 1 μL of decreased storage volume. For serial transfer treatment, the unit of change is one transfer, that is, the amount of Aβ lost per transfer of sample to another tube.
